**Supplementary material**

**Temporal trends in low-dose aspirin use: the CoLaus|PsyCoLaus Study**

*Drai et al.*

**Supplementary Table 1.** Factors associated with the prescription of aspirin in primary prevention at baseline (2003-2009), first (2009-2012), second (2047-2017) and third (2019-2021) follow-ups

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **2003-2006** | **P-value** | **2009-2012** | **P-value** | **2014-2017** | **P-value** |
| Sample size | 6555 |  | 4695 |  | 3893 |  |
| Male vs. female | 1.29 (1.00 - 1.67) | 0.052 | 1.07 (0.82 - 1.39) | 0.627 | 0.92 (0.70 - 1.20) | 0.528 |
| Age (per 1-y increase) | 1.08 (1.07 - 1.10) | <0.001 | 1.08 (1.06 - 1.09) | <0.001 | 1.08 (1.07 - 1.10) | <0.001 |
| Education |  |  |  |  |  |  |
| High | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
| Middle | 1.29 (0.84 - 1.97) | 0.246 | 0.85 (0.58 - 1.24) | 0.399 | 0.94 (0.63 - 1.40) | 0.759 |
| Low | 1.23 (0.84 - 1.81) | 0.285 | 0.71 (0.50 - 1.01) | 0.054 | 0.97 (0.68 - 1.38) | 0.854 |
| Smoking status |  |  |  |  |  |  |
| Never | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
| Former | 1.52 (1.14 - 2.03) | 0.004 | 1.20 (0.91 - 1.59) | 0.196 | 1.34 (1.01 - 1.79) | 0.042 |
| Current | 1.84 (1.34 - 2.53) | <0.001 | 1.53 (1.08 - 2.18) | 0.018 | 2.30 (1.62 - 3.27) | <0.001 |
| Risk factors (yes vs. no) |  |  |  |  |  |  |
| Family history | 1.10 (0.86 - 1.40) | 0.457 | 0.97 (0.76 - 1.25) | 0.840 | 1.15 (0.89 - 1.48) | 0.292 |
| Hypertension | 2.61 (1.95 - 3.50) | <0.001 | 3.22 (2.35 - 4.39) | <0.001 | 3.34 (2.43 - 4.58) | <0.001 |
| Hypercholesterolemia | 1.02 (0.95 - 1.09) | 0.539 | 2.35 (1.84 - 3.01) | <0.001 | 0.99 (0.93 - 1.06) | 0.856 |
| Diabetes | 2.54 (1.86 - 3.47) | <0.001 | 3.07 (2.31 - 4.08) | <0.001 | 3.63 (2.66 - 4.93) | <0.001 |
| BMI categories |  |  |  |  |  |  |
| Normal | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
| Overweight | 1.11 (0.83 - 1.49) | 0.464 | 1.35 (0.99 - 1.85) | 0.056 | 1.13 (0.82 - 1.54) | 0.453 |
| Obese | 1.41 (1.01 - 1.97) | 0.047 | 1.90 (1.34 - 2.70) | <0.001 | 1.89 (1.34 - 2.67) | <0.001 |

Results are expressed as multivariate-adjusted odds ratio and (95% confidence interval). Statistical analysis by logistic regression. BMI, body-mass index.

**Supplementary Table 2.** Participants’ baseline characteristics in secondary prevention, according to low-dose aspirin use

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics** | **Total** | **Non aspirin users** | **Low-dose aspirin users** | ***p-value*** |
| N | 149 | 42 | 107 |  |
| Women (%)  | 43 (28.9) | 16 (38.1) | 27 (25.2) | 0.119 |
| Age (years) | 62.2 ± 9.1 | 60.5 ± 10.0 | 62.8 ± 8.7 | 0.158 |
| Age groups (%) |  |  |  | 0.695 |
| 35-44 years | 10 (6.7) | 4 (9.5) | 6 (5.6) |  |
| 45-54 years | 20 (13.4) | 7 (16.7) | 13 (12.2) |  |
| 55-64 years | 56 (37.6) | 15 (35.8) | 41 (38.3) |  |
| ≥ 65 years | 63 (42.3) | 16 (38.1) | 47 (43.9) |  |
| Education (%) |  |  |  | 0.618 |
| High | 21 (14.2) | 5 (12.2) | 16 (15.0) |  |
| Middle | 32 (21.6) | 11 (26.8) | 21 (19.6) |  |
| Low | 95 (64.2) | 25 (61.0) | 70 (65.4) |  |
| Body mass index (kg/m2) | 28.1 ± 4.4 | 28.8 ± 5.0 | 27.9 ± 4.2 | 0.228 |
| BMI categories (%) |  |  |  | 0.315 |
| Normal | 36 (24.2) | 10 (23.8) | 26 (24.3) |  |
| Overweight | 69 (46.3) | 16 (38.1) | 53 (49.5) |  |
| Obese | 44 (29.5) | 16 (38.1) | 28 (26.2) |  |
| Smoking status (%) |  |  |  | 0.891 |
| Never | 29 (19.6) | 13 (31.7) | 16 (14.9) |  |
| Former | 90 (60.8) | 19 (46.3) | 71 (66.4) |  |
| Current | 29 (19.6) | 9 (22.0) | 20 (18.7) |  |
| Diabetes mellitus (%) | 28 (18.8) | 7 (16.7) | 21 (19.6) | 0.677 |
| Hypertension (%) | 134 (89.9) | 34 (81.0) | 100 (93.5) | 0.022 |
| Lipid values (mmol/L) |  |  |  |  |
| Total cholesterol | 5.14 ± 1.04 | 5.29 ± 0.98 | 5.07 ± 1.06 | 0.250 |
| LDL cholesterol | 2.99 ± 0.91 | 3.15 ± 0.94 | 2.93 ± 0.89 | 0.198 |
| HDL cholesterol | 1.44 ± 0.38 | 1.45 ± 0.46 | 1.43 ± 0.35 | 0.842 |
| Statin use (%) | 87 (58.4) | 17 (40.5) | 70 (65.4) | 0.005 |
| Family history of CHD (%) | 59 (39.6) | 17 (40.5) | 42 (39.3) | 0.891 |
| Anticoagulants (%) | 16 (10.7) | 6 (14.3) | 10 (9.4) | 0.381 |
| Clopidogrel (%) | 21 (14.1) | 7 (16.7) | 14 (13.1) | 0.572 |

BMI, body mass index; CHD, coronary heart disease. Results are expressed as number of participants (column %) for categorical variables and as average ± standard deviation for continuous variables. Between-groups comparisons performed using chi-square for categorical variables and student’s t-test for continuous variables.

**Supplementary Table 3.** Factors associated with the prescription of aspirin in secondary prevention at baseline (2003-2009), first (2009-2012), second (2047-2017) and third (2019-2021) follow-ups

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **2003-2006** | **P-value** | **2009-2012** | **P-value** | **2014-2017** | **P-value** |
| Sample size | 149 |  | 237 |  | 346 |  |
| Male vs. female | 1.39 (0.58 - 3.34) | 0.466 | 1.57 (0.75 - 3.29) | 0.232 | 0.94 (0.50 - 1.74) | 0.834 |
| Age (per 1-y increase) | 1.01 (0.96 - 1.05) | 0.829 | 1.00 (0.96 - 1.04) | 0.915 | 0.99 (0.96 - 1.02) | 0.644 |
| Education |  |  |  |  |  |  |
| High | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
| Middle | 0.43 (0.10 - 1.79) | 0.248 | 0.44 (0.13 - 1.48) | 0.183 | 0.60 (0.22 - 1.65) | 0.322 |
| Low | 0.76 (0.22 - 2.60) | 0.657 | 0.41 (0.14 - 1.20) | 0.103 | 0.59 (0.24 - 1.45) | 0.252 |
| Smoking status |  |  |  |  |  |  |
| Never | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
| Former | 3.69 (1.36 - 10.0) | 0.010 | 1.00 (0.44 - 2.27) | 0.996 | 1.27 (0.68 - 2.38) | 0.449 |
| Current | 2.22 (0.64 - 7.63) | 0.207 | 0.78 (0.29 - 2.08) | 0.620 | 2.51 (0.98 - 6.41) | 0.055 |
| Risk factors (yes vs. no) |  |  |  |  |  |  |
| Family history | 1.06 (0.46 - 2.45) | 0.885 | 1.89 (0.95 - 3.75) | 0.068 | 1.62 (0.90 - 2.93) | 0.109 |
| Hypertension | 3.62 (0.89 - 14.7) | 0.072 | 2.11 (0.80 - 5.57) | 0.133 | 2.30 (1.02 - 5.19) | 0.045 |
| Hypercholesterolemia | 2.03 (0.88 - 4.69) | 0.099 | 1.40 (0.70 - 2.78) | 0.342 | 0.89 (0.75 - 1.06) | 0.200 |
| Diabetes | 1.35 (0.45 - 4.05) | 0.591 | 0.94 (0.44 - 1.98) | 0.861 | 1.40 (0.69 - 2.85) | 0.351 |
| BMI categories |  |  |  |  |  |  |
| Normal | 1 (ref) |  | 1 (ref) |  | 1 (ref) |  |
| Overweight | 0.80 (0.28 - 2.27) | 0.668 | 0.48 (0.21 - 1.10) | 0.084 | 0.94 (0.48 - 1.85) | 0.868 |
| Obese | 0.30 (0.09 - 0.99) | 0.049 | 0.82 (0.31 - 2.21) | 0.698 | 0.87 (0.39 - 1.92) | 0.724 |

Results are expressed as multivariate-adjusted odds ratio and (95% confidence interval). Statistical analysis by logistic regression. BMI, body-mass index.

**Supplementary Table 4**. Evolution of low-dose aspirin use by age range.

|  |  |  |  |
| --- | --- | --- | --- |
| **Age group** | **Baseline** | **Follow-up 1** | **Follow-up 2** |
| Primary prevention |  |  |
| [35-44] | 14 (0.7) | 7 (1.2) | 0 |
| [45-54] | 45 (2.3) | 27 (1.7) | 13 (1.1) |
| [55-64] | 134 (7.8) | 93 (7.3) | 73 (5.8) |
| [65+ | 131 (14.0) | 213 (17.2) | 245 (16.8) |
| Secondary prevention |  |  |
| [35-44] | 6 (60.0) | 2 (50.0) |  |
| [45-54] | 13 (65.0) | 20 (71.4) | 19 (59.4) |
| [55-64] | 41 (73.2) | 45 (75.0) | 48 (77.4) |
| [65+ | 47 (74.6) | 113 (77.9) | 181 (71.8) |

Results expressed as number of people and (row percentage).

**Supplementary Table 5**. Comparison of characteristics of the participants included in the analyses and those lost to follow-up (deaths excluded)

|  |  |  |
| --- | --- | --- |
|  | **Baseline to first follow-up** | **First to second follow-up** |
|  | **Included** | **Lost to FU** | **P-value** | **Included** | **Lost to FU** | **P-value** |
| N | 5,064 | 1,426 |  | 4,334 | 571 |  |
| Women (%)  | 2,707 (53.5) | 744 (52.2) | 0.392 | 2,382 (55.0) | 265 (46.4) | <0.001 |
| Age groups (%) |  |  | 0.678 |  |  | 0.014 |
| 35-44 years | 1,534 (30.3) | 439 (30.8) |  | 559 (12.9) | 65 (11.4) |  |
| 45-54 years | 1,515 (29.9) | 408 (28.6) |  | 1,407 (32.5) | 222 (38.9) |  |
| 55-64 years | 1,333 (26.3) | 373 (26.2) |  | 1,173 (27.1) | 151 (26.4) |  |
| ≥ 65 years | 682 (13.5) | 206 (14.5) |  | 1,195 (27.6) | 133 (23.3) |  |
| Education (%) |  |  | <0.001 |  |  | 0.001 |
| High | 1,079 (21.3) | 210 (14.8) |  | 949 (21.9) | 104 (18.3) |  |
| Middle | 1,306 (25.8) | 278 (19.6) |  | 1,147 (26.5) | 125 (22.0) |  |
| Low | 2,674 (52.9) | 931 (65.6) |  | 2,235 (51.6) | 340 (59.8) |  |
| BMI categories (%) |  |  | <0.001 |  |  | 0.004 |
| Normal | 2,505 (49.5) | 618 (43.4) |  | 1,916 (44.7) | 210 (37.4) |  |
| Overweight | 1,852 (36.6) | 524 (36.8) |  | 1,664 (38.8) | 242 (43.1) |  |
| Obese | 706 (13.9) | 282 (19.8) |  | 704 (16.4) | 109 (19.4) |  |
| Smoking status (%) |  |  | <0.001 |  |  | <0.001 |
| Never | 2,063 (40.8) | 612 (43.0) |  | 1,775 (41.4) | 225 (39.9) |  |
| Former | 1,700 (33.6) | 401 (28.2) |  | 1,632 (38.1) | 179 (31.7) |  |
| Current | 1,299 (25.7) | 410 (28.8) |  | 882 (20.6) | 160 (28.4) |  |
| Diabetes mellitus (%) | 285 (5.6) | 108 (7.6) | 0.006 | 438 (10.1) | 68 (12.0) | 0.179 |
| Hypertension (%) | 1,745 (34.5) | 608 (42.7) | <0.001 | 1,738 (40.2) | 253 (44.5) | 0.045 |

FU, follow-up; BMI, body-mass index.